Literature DB >> 21074720

Aberrant epigenetic landscape in cancer: how cellular identity goes awry.

María Berdasco1, Manel Esteller.   

Abstract

Appropriate patterns of DNA methylation and histone modifications are required to assure cell identity, and their deregulation can contribute to human diseases, such as cancer. Our aim here is to provide an overview of how epigenetic factors, including genomic DNA methylation, histone modifications, and microRNA regulation, contribute to normal development, paying special attention to their role in regulating tissue-specific genes. In addition, we summarize how these epigenetic patterns go awry during human cancer development. The possibility of "resetting" the abnormal cancer epigenome by applying pharmacological or genetic strategies is also discussed.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21074720     DOI: 10.1016/j.devcel.2010.10.005

Source DB:  PubMed          Journal:  Dev Cell        ISSN: 1534-5807            Impact factor:   12.270


  229 in total

1.  DNA methylation screening and analysis.

Authors:  Karilyn E Sant; Muna S Nahar; Dana C Dolinoy
Journal:  Methods Mol Biol       Date:  2012

2.  In silico analysis of regulatory and structural motifs of the ovine HSP90AA1 gene.

Authors:  Carmen González; Judit Salces-Ortiz; Jorge H Calvo; M Magdalena Serrano
Journal:  Cell Stress Chaperones       Date:  2016-01-26       Impact factor: 3.667

3.  Fbxl10 overexpression in murine hematopoietic stem cells induces leukemia involving metabolic activation and upregulation of Nsg2.

Authors:  Takeshi Ueda; Akiko Nagamachi; Keiyo Takubo; Norimasa Yamasaki; Hirotaka Matsui; Akinori Kanai; Yuichiro Nakata; Kenichiro Ikeda; Takaaki Konuma; Hideaki Oda; Linda Wolff; Zen-ichiro Honda; Xudong Wu; Kristian Helin; Atsushi Iwama; Toshio Suda; Toshiya Inaba; Hiroaki Honda
Journal:  Blood       Date:  2015-04-14       Impact factor: 22.113

4.  Association between epidermal growth factor receptor amplification and ADP-ribosylation factor 1 methylation in human glioblastoma.

Authors:  Concha López-Ginés; Lara Navarro; Lisandra Muñoz-Hidalgo; Enrique Buso; José Manuel Morales; Rosario Gil-Benso; Mariela Gregori-Romero; Javier Megías; Pedro Roldán; Remedios Segura-Sabater; José Manuel Almerich-Silla; Daniel Monleón; Miguel Cerdá-Nicolás
Journal:  Cell Oncol (Dordr)       Date:  2017-06-19       Impact factor: 6.730

Review 5.  Epigenetics and colorectal cancer.

Authors:  Victoria Valinluck Lao; William M Grady
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-10-18       Impact factor: 46.802

6.  Global methylation and promoter-specific methylation of the P16, SOCS-1, E-cadherin, P73 and SHP-1 genes and their expression in patients with multiple myeloma during active disease and remission.

Authors:  Déborah Martínez-Baños; Beatríz Sánchez-Hernández; Guadalupe Jiménez; Georgina Barrera-Lumbreras; Olga Barrales-Benítez
Journal:  Exp Ther Med       Date:  2017-03-28       Impact factor: 2.447

7.  KDM5A silencing transcriptionally suppresses the FXYD3-PI3K/AKT axis to inhibit angiogenesis in hepatocellular cancer via miR-433 up-regulation.

Authors:  Yu-Shui Ma; Ting-Miao Wu; Bin Qian; Yu-Shan Liu; Hua Ding; Ming-Ming Fan; Ji-Bin Liu; Fei Yu; Hui-Min Wang; Yi Shi; Li-Peng Gu; Liu Li; Lin-Lin Tian; Pei-Yao Wang; Gao-Ren Wang; Zhi-Jun Wu; Qi-Fei Zou; Chang-Chun Ling; Da Fu
Journal:  J Cell Mol Med       Date:  2021-02-23       Impact factor: 5.310

Review 8.  Cell plasticity and heterogeneity in cancer.

Authors:  Nemanja D Marjanovic; Robert A Weinberg; Christine L Chaffer
Journal:  Clin Chem       Date:  2012-12-06       Impact factor: 8.327

9.  Global methylation profiling to identify epigenetic signature of gallbladder cancer and gallstone disease.

Authors:  Preeti Sharma; Shushruta Bhunia; Satish S Poojary; Dinesh S Tekcham; Mustafa Ahmed Barbhuiya; Sanjiv Gupta; Braj Raj Shrivastav; Pramod Kumar Tiwari
Journal:  Tumour Biol       Date:  2016-09-14

Review 10.  CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer.

Authors:  M Sachdeva; N Sachdeva; M Pal; N Gupta; I A Khan; M Majumdar; A Tiwari
Journal:  Cancer Gene Ther       Date:  2015-10-23       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.